The trajectory of companies tied to the drug's past presents a challenging investment scenario . While the initial success generated substantial gains, generic copies have significantly eroded revenue. Investing in associated pharmaceutical companies now requires a careful assessment of intellectual property rights , evolving patient changes, and t